MCRB Seres Therapeutics, Inc.

Nasdaq serestherapeutics.com


$ 18.96 $ -0.35 (-1.82 %)    

Friday, 17-Oct-2025 15:58:20 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 18.91
$ 19.30
$ 18.40 x 30
$ 20.75 x 335
$ 18.72 - $ 19.30
$ 6.53 - $ 24.67
79,422
na
165.55M
$ 1.20
$ 1.93
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 03-02-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 07-28-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 seres-therapeutics-announces-actions-to-reduce-operating-costs-reducing-workforce-by-about-25-workforce-reduction-to-result-in-cash-charges-of-1m-14m

On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to...

 seres-therapeutics-receives-fda-feedback-to-finalize-phase-2-protocol-for-ser-155-in-preventing-bsis-in-allo-hsct-patients

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of b...

 seres-therapeutics-q2-eps-227-beats-265-estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(...

 chardan-capital-downgrades-seres-therapeutics-to-neutral-raises-price-target-to-6

Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price targ...

 seres-therapeutics-q1-eps-375-beats-012-estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION